These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 2480743)
1. Protection against experimental Pseudomonas infection with O antigen-specific human monoclonal antibodies. Sawada S; Kawamura T; Masuho Y; Iyobe S; Hashimoto H Antibiot Chemother (1971); 1989; 42():210-7. PubMed ID: 2480743 [No Abstract] [Full Text] [Related]
2. In vitro and in vivo functional activities of monoclonal antibodies reactive with Pseudomonas aeruginosa serogroup 6 lipopolysaccharides. Pollack M; Tao M; Akiyama M; Pier GB; Koles NL Antibiot Chemother (1971); 1991; 44():163-71. PubMed ID: 1801635 [No Abstract] [Full Text] [Related]
3. Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa. Collins MS; Ladehoff DK; Mehton NS; Noonan JS FEMS Microbiol Immunol; 1990 Dec; 2(5-6):263-8. PubMed ID: 2127368 [TBL] [Abstract][Full Text] [Related]
4. Immunization with a Pseudomonas aeruginosa 1244 pilin provides O-antigen-specific protection. Horzempa J; Held TK; Cross AS; Furst D; Qutyan M; Neely AN; Castric P Clin Vaccine Immunol; 2008 Apr; 15(4):590-7. PubMed ID: 18272666 [TBL] [Abstract][Full Text] [Related]
5. Broad-spectra human monoclonal antibodies that protect mice infected with Pseudomonas aeruginosa. Noguchi H; Yokota S; Ohtsuka H; Kohzuki T; Terashima M; Irie K Antibiot Chemother (1971); 1991; 44():172-84. PubMed ID: 1724892 [No Abstract] [Full Text] [Related]
6. [Investigation on the protection of mice from infection with Pseudomonas aeruginosa using monoclonal antibodies]. Ye DN; Wang CX; Yan RH; Dai BM; Ni HY Sichuan Yi Xue Yuan Xue Bao; 1985 Sep; 16(3):188-90. PubMed ID: 3939267 [No Abstract] [Full Text] [Related]
7. Immunological reactivity and passive protective activity of monoclonal antibodies against protective antigen (PAg) of Leptospira interrogans serovar lai. Masuzawa T; Nakamura R; Hashiguchi Y; Shimizu T; Iwamoto Y; Morita T; Yanagihara Y Zentralbl Bakteriol; 1990 Mar; 272(3):328-36. PubMed ID: 2331299 [TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies to Salmonella lipopolysaccharide: anti-O-polysaccharide antibodies protect C3H mice against challenge with virulent Salmonella typhimurium. Colwell DE; Michalek SM; Briles DE; Jirillo E; McGhee JR J Immunol; 1984 Aug; 133(2):950-7. PubMed ID: 6203984 [TBL] [Abstract][Full Text] [Related]
9. Structural analysis of the lipopolysaccharide O-antigen from Cairns CM; St Michael F; Fleming P; Vinogradov EV; Cox AD Can J Microbiol; 2020 Sep; 66(9):529-534. PubMed ID: 32396022 [No Abstract] [Full Text] [Related]
10. Protection of mice against P. aeruginosa infections by large-scale affinity-purified human IgG specific to P. aeruginosa outer membrane proteins. Lee NG; Jung SB; Ahn BY; Kim YG; Lee Y; Jeon YJ; Park WJ Vaccine; 1999 Nov; 18(7-8):665-74. PubMed ID: 10547426 [TBL] [Abstract][Full Text] [Related]
11. Immunoprotective human monoclonal antibodies against five major serotypes of Pseudomonas aeruginosa. Sawada S; Kawamura T; Masuho Y J Gen Microbiol; 1987 Dec; 133(12):3581-90. PubMed ID: 3141560 [TBL] [Abstract][Full Text] [Related]
12. Protection against Pseudomonas aeruginosa infection by passive transfer of anti-flagellar serum. Drake D; Montie TC Can J Microbiol; 1987 Sep; 33(9):755-63. PubMed ID: 3121159 [TBL] [Abstract][Full Text] [Related]
13. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa. Sawa T; Ito E; Nguyen VH; Haight M Hum Vaccin Immunother; 2014; 10(10):2843-52. PubMed ID: 25483637 [TBL] [Abstract][Full Text] [Related]
14. N-acetyl-L-galactosaminuronic acid as an epitope common to the O-polysaccharides of Pseudomonas aeruginosa serotype A and H (Homma) recognized by a protective human monoclonal antibody. Yokota S; Ochi H; Uezumi I; Ohtsuka H; Irie K; Noguchi H Eur J Biochem; 1990 Aug; 192(1):109-13. PubMed ID: 1698155 [TBL] [Abstract][Full Text] [Related]
15. Protection against infection with Pseudomonas aeruginosa by passive transfer of monoclonal antibodies to lipopolysaccharides and outer membrane proteins. Sawada S; Suzuki M; Kawamura T; Fujinaga S; Masuho Y; Tomibe K J Infect Dis; 1984 Oct; 150(4):570-6. PubMed ID: 6436393 [TBL] [Abstract][Full Text] [Related]
16. Properties determining the potential of naturally occurring and vaccine-induced human antibodies to protect against lethal infection of Pseudomonas aeruginosa. Bruderer U; Fürer E; Cryz SJ; Lang AB Res Immunol; 1992 Feb; 143(2):165-74. PubMed ID: 1374194 [TBL] [Abstract][Full Text] [Related]
18. Opsonic monoclonal antibodies against lipopolysaccharide (LPS) antigens of Pasteurella multocida and the role of LPS in immunity. Ramdani ; Adler B Vet Microbiol; 1991 Feb; 26(4):335-47. PubMed ID: 1709544 [TBL] [Abstract][Full Text] [Related]
19. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization. Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420 [TBL] [Abstract][Full Text] [Related]
20. Characterization and specificity controls of murine monoclonal antibodies against serogroup C1 Salmonella. Tsang RS; Aleksić S; Chan KH; Lau NW; Ng MH Diagn Microbiol Infect Dis; 1992; 15(3):213-23. PubMed ID: 1374696 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]